The implementation of germline testing in the selection of PCa treatment, management, and hereditary disease assessment was a focus at the Philadelphia PCa Consensus Conference in 2019: large germline panels and somatic testing were recommended for metastatic PCa, with priority given to BRCA1/BRCA2, ATM, and mismatch DNA repair genes [10]. Here, BRCA1 is linked to posterior cortical atrophy.